Inhibition of capillary repair in proliferative glomerulonephritis results in persistent glomerular inflammation with glomerular sclerosis

Laboratory Investigation

Volumn 90, Issue 10, 2010, Pages 1468-1481

  Masuda, Yukinari ^a   Shimizu, Akira ^a   Kataoka, Mitue ^a   Arai, Takashi ^a   Ishikawa, Arimi ^a   Du, Xuanyi ^a   Saito, Sabine Kyoko ^a   Aki, Kaoru ^a   Nagasaka, Shinya ^a   Mii, Akiko ^a   Fujita, Emiko ^a   Fukuda, Yuh ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

anti VEGF neutralizing antibody; capillary repair; endothelial cells; glomerulonephritis; inflammation; vascular endothelial growth factor

Indexed keywords

COLLAGEN TYPE 1; THY 1 ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 164; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; HISTOPATHOLOGY; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN EXPRESSION; PROTEINURIA; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CAPILLARIES; CELL COUNT; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; INFLAMMATION; ISOANTIBODIES; KIDNEY FUNCTION TESTS; KIDNEY GLOMERULUS; MACROPHAGES; MALE; RATS; RATS, WISTAR; REGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957277209     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.130     Document Type: Article

References (47)

1. Ballerman BJ. Endothelial responses to immune injury. In: Neilson EG and Couser WG (eds) Immunologic Renal Diseases. Lippincott-Raven Publishers: Philadelphia, PA, 1997, pp 627-654.
2. Yamanaka N, Shimizu A. Role of glomerular endothelial damage in progressive renal disease. Kidney Blood Press Res 1999;22:13-20. (Pubitemid 29243442)
3. Ballerman BJ. Contribution of the endothelium to the glomerular permselectivity barrier in health and disease. Nephron Physiol 2007;106:19-25.
4. Kang DH, Johnson RJ. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 2003;12:43-49. (Pubitemid 36092314)
5. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol 2007;18:2281-2284.
6. Kitamura H, Sugisaki Y, Yamanaka N. Endothelial regeneration during the repair process following Habu-snake venom induced glomerular injury. Virchows Arch 1995;427:195-204.
7. Ostendorf T, Kunter U, Eitner F, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999;104:913-923. (Pubitemid 29536341)
8. Masuda Y, Shimizu A, Mori T, et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001;159: 599-608. (Pubitemid 32751090)
9. Shimizu A, Masuda Y, Mori T, et al. Vascular endothelial growth factor 165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 2004;15:2655-2665. (Pubitemid 41103372)
10. Kim YG, Suga S, Kang DH, et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 2000;58:2390-2399.
11. Iruela-Arispe L, Gordon K, Hugo C, et al. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 1995;147:1715-1727.
12. Shimizu A, Masuda Y, Kitamura H, et al. Recovery of damaged glomerular capillary network with endothelial cell apoptosis in experimental proliferative glomerulonephritis. Nephron 1998;79:206-214. (Pubitemid 28256567)
13. Shimizu A, Masuda Y, Kitamura H, et al. Complement-mediated killing of mesangial cells in experimental glomerulonephritis: cell death by a combination of apoptosis and necrosis. Nephron 2000;86:152-160.
14. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999;237:1-30. (Pubitemid 28554856)
15. Klanke B, Simon M, Röckl W, et al. Effects of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) on haemodynamics and permselectivity of the isolated perfused rat kidney. Nephrol Dial Transplant 1998;13:875-885. (Pubitemid 28161758)
16. Schrjvers BF, Flyvbjerg A, Vriese AD. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004;65: 2003-2017. (Pubitemid 38669987)
17. Ostendorf T, De Vriese AS, Floege J. Renal side effects of anti-VEGF therapy in man: a new test system. Nephrol Dial Transplant 2007;22: 2778-2780. (Pubitemid 350093418)
18. Simö R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008;51: 1574-1580.
19. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (avastin) a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-335. (Pubitemid 40848295)
20. van Wijingaarden P, Qureshi SH. Inhibitions vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Clin Exp Optom 2008;91:427-437.
21. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007;13:1098-1106.
22. Eremina V, Jefferson A, Ko walewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1135. (Pubitemid 351398487)
23. Kapiteijn E, Brand A, Kroep J, et al. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007;18:1745-1747. (Pubitemid 47506266)
24. Stokes MB, Erazo MC, DAgati VD. Glomerular disease related to anti-VEGF therapy. Kidney Int 2008;74:1487-1491.
25. Mastui Y, Mitsuyama K, Tomiyama N, et al. Efficacy of vascular endothelial growth factor in the treatment of experimental gastric injury. Digestion 2002;66:99-105. (Pubitemid 35356690)
26. Kondo S, Asano M, Suzuki H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth and its inhibition by the antibody. Biochem Biophys Res Commun 1993;194:1234-1241. (Pubitemid 23255013)
27. Nangaku M, Pippin J, Richardson CA, et al. Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. Kidney Int 1996;50:2054-2062. (Pubitemid 26417550)
28. Jefferson JA, Suga SI, Kim YG, et al. Intravenous immunoglobulin protects against experimental thrombotic microangiopathy. Kidney Int 2001;60:1018-1025.
29. Horvat R, Palade GE. Thrombomodulin and thrombin localization on the vasculature endothelium: their internalization and transcytosis by plasmalemmal vesicles. Eur J Cell Biol 1993;61:299-313. (Pubitemid 23307542)
30. Nagashima M, Yoshino S, Ishiwata T, et al. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995;22:1624-1630.
31. Floege J, Ostendorf T, Janssen U, et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am J Pathol 1999;154: 169-179. (Pubitemid 29031624)
32. Hugo C, Pichler R, Gordon K, et al. The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis. J Clin Invest 1996;97:2499-2508. (Pubitemid 26187337)
33. Modelli de Andrade LG, Viero RM, Carvalho MF. Role of peritubular capillaries and vascular endothelial growth factor in chronic allograft nephropathy. Transplant Proc 2009;41:3720-3725.
34. Choi YJ, Chakraborty S, Nguyen V, et al. Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Hum Pathol 2000;31:1491-1497. (Pubitemid 32049007)
35. Ohashi R, Kitamura H, Yamanaka N. Peritubular capillary injury during the progression of experimental glomerulonephritis in rats. J Am Soc Nephrol 2001;11:47-56. (Pubitemid 30020425)
36. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model: I potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001;12:1434-1447. (Pubitemid 32666326)
37. Ohashi R, Shimizu A, Masuda Y, et al. Peritubular capillary regression during the progression of experimental obstructive nephropathy. J Am Soc Nephrl 2002;13:1795-1805. (Pubitemid 34700604)
38. Kang DH, Hughes J, Mazzali M, et al. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001;12:1448-1457. (Pubitemid 32666327)
39. Konda R, Sato H, Sakai K, et al. Expression of platelet-derived endothelial cell growth factor and its potential role in up-regulation of angiogenesis in scarred kidneys secondary to urinary tract diseases. Am J Pathol 1999;155:1587-1597.
40. Eremina V, Baelde HJ, Quaggin AE. Role of the VEGF-A signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 2007;106:32-37. (Pubitemid 46920098)
41. Maynard SE, Min JY, Mechan J, et al. Excess placental soluble fms-like tyrosine kinase 1(sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111: 649-658.
42. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Bio Chem 2003;278:12605-12608. (Pubitemid 36800018)
43. De Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993-1000. (Pubitemid 32378340)
44. Eremina V, Cui S, Gerber H, et al. Vascular endothelial growth factor A signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006;17: 724-735.
45. Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009;20:81-82.
46. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-193. (Pubitemid 46178407)
47. Izzedine H, Rixe O, Billemont B, et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007;50: 203-218. (Pubitemid 47095077)